GlobalPost reports on HIV/AIDS in Latin America

In its continuing series titled "The State of AIDS," GlobalPost examines the HIV/AIDS epidemic in Latin America and the Caribbean, where "[m]ajor gains have been made in the fight against the spread of HIV" over the past decade, particularly in stopping mother-to-child transmission (MTCT). However, some countries in the region have some of the highest HIV/AIDS prevalence rates outside of sub-Saharan Africa; "the disease continues to spread among certain at-risk populations," such as men who have sex with men; and "nearly one-third of those infected in Latin America are still not getting treated," the news service reports.

In Latin America "stabilization of the epidemic is not a success," Cesar Nunez, regional director of UNAIDS, said in an interview with GlobalPost, adding, "It reflects slow and fragile progress with modest gains," according to the news service. Nunez said if gains in stopping MTCT "can be scaled up quickly and effectively throughout the region, Latin America could become one of the first regions in the world to achieve the vision of zero babies born with HIV," the news service notes (Miroff, 12/5). GlobalPost also features an infographic on the global state of the epidemic (Kim, 12/6).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Affordability and supply remain critical to the success of long-lasting HIV drug